Avorn J, Monane M, Everitt D E, Beers M H, Fields D
Department of Medicine, Harvard Medical School, Boston, MA.
Arch Intern Med. 1994 May 23;154(10):1113-7.
We sought to quantify the relationship between antipsychotic drug use and clinical evidence of extrapyramidal dysfunction in a large population of elderly nursing home patients.
Subjects were 251 residents (mean age, 84.1 years; range, 65 to 105 years) who were taking psychoactive drugs in 12 long-term care facilities. Patient characteristics and all medication use (both scheduled and as needed) were measured during a 1-month observation period. We then performed neuropsychological and functional testing on residents who received any psychoactive medications during the study month. The presence of rigidity, bradykinesia, or masklike facies was assessed in each patient by a research assistant who was unaware of diagnoses and medication use.
The parkinsonian signs studied were found in 127 (50.6%) of these residents. Using logistic regression modeling to adjust for potential confounding, we found this outcome to be increased more than threefold in patients who took low-potency neuroleptics (odds ratio [OR], 3.49 for > or = 50 mg/d of chlorpromazine-type drugs; 95% confidence interval [CI], 1.28 to 9.57) and more than sixfold for use of 1 mg/d or more of haloperidol (OR, 6.42; 95% CI, 2.16 to 19.04). Age, gender, and use of nonneuroleptic psychoactive drugs were not associated with an increase in parkinsonian signs.
Clinical evidence of extrapyramidal dysfunction is three to six times more common in institutionalized elderly patients given antipsychotic medication than in comparable patients not using such drugs. Its risk is substantially increased even in patients given low-potency chlorpromazine-type drugs, as well as those taking haloperidol. The effect is not explained by age or mental status and is not seen with other psychoactive medications. The expected frequency of parkinsonian symptoms can help to inform the balancing of risks vs therapeutic effect when the use of all drugs in this class is considered.
我们试图在大量老年疗养院患者中量化抗精神病药物使用与锥体外系功能障碍临床证据之间的关系。
研究对象为12家长期护理机构中正在服用精神活性药物的251名居民(平均年龄84.1岁;范围65至105岁)。在1个月的观察期内测量患者特征和所有药物使用情况(包括定期用药和按需用药)。然后,我们对研究月内接受任何精神活性药物治疗的居民进行了神经心理学和功能测试。由一名不了解诊断和用药情况的研究助理对每位患者进行僵硬、运动迟缓或面具脸的评估。
在这些居民中,127名(50.6%)出现了所研究的帕金森氏体征。使用逻辑回归模型对潜在混杂因素进行调整后,我们发现服用低效神经阻滞剂的患者出现这种结果的几率增加了三倍多(氯丙嗪类药物每日剂量≥50mg时,比值比[OR]为3.49;95%置信区间[CI]为1.28至9.57),而每日服用1mg或更多氟哌啶醇的患者出现这种结果的几率增加了六倍多(OR为6.42;95%CI为2.16至19.04)。年龄、性别和非神经阻滞剂类精神活性药物的使用与帕金森氏体征的增加无关。
与未使用此类药物的类似患者相比,接受抗精神病药物治疗的机构化老年患者出现锥体外系功能障碍临床证据的可能性要高三至六倍。即使是服用低效氯丙嗪类药物的患者以及服用氟哌啶醇的患者,其风险也会大幅增加。这种影响不能用年龄或精神状态来解释,其他精神活性药物也不会出现这种情况。在考虑使用此类所有药物时,帕金森氏症状的预期发生率有助于权衡风险与治疗效果。